496 related articles for article (PubMed ID: 28287251)
21. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling.
Watson JL; Greenshields A; Hill R; Hilchie A; Lee PW; Giacomantonio CA; Hoskin DW
Mol Carcinog; 2010 Jan; 49(1):13-24. PubMed ID: 19676105
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation.
Mansouri A; Zhang Q; Ridgway LD; Tian L; Claret FX
Oncol Res; 2003; 13(6-10):399-404. PubMed ID: 12725530
[TBL] [Abstract][Full Text] [Related]
23. Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line.
Vaskivuo L; Rysä J; Koivuperä J; Myllynen P; Vaskivuo T; Chvalova K; Serpi R; Savolainen ER; Puistola U; Vähäkangas K
Toxicol Appl Pharmacol; 2006 Oct; 216(1):89-97. PubMed ID: 16797627
[TBL] [Abstract][Full Text] [Related]
24. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
25. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
[TBL] [Abstract][Full Text] [Related]
26. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
27. ERK1/2/p53 and NF-κB dependent-PUMA activation involves in doxorubicin-induced cardiomyocyte apoptosis.
Zhang DX; Ma DY; Yao ZQ; Fu CY; Shi YX; Wang QL; Tang QQ
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2435-42. PubMed ID: 27338072
[TBL] [Abstract][Full Text] [Related]
28. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells.
Lee S; Yoon S; Kim DH
Gynecol Oncol; 2007 Feb; 104(2):338-44. PubMed ID: 17023032
[TBL] [Abstract][Full Text] [Related]
29. ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes.
Liu J; Mao W; Ding B; Liang CS
Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H1956-65. PubMed ID: 18775851
[TBL] [Abstract][Full Text] [Related]
30. RNA interference targeting slug increases cholangiocarcinoma cell sensitivity to cisplatin via upregulating PUMA.
Zhang K; Chen D; Wang X; Zhang S; Wang J; Gao Y; Yan B
Int J Mol Sci; 2011 Jan; 12(1):385-400. PubMed ID: 21339993
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal--regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines.
Cui W; Yazlovitskaya EM; Mayo MS; Pelling JC; Persons DL
Mol Carcinog; 2000 Dec; 29(4):219-28. PubMed ID: 11170260
[TBL] [Abstract][Full Text] [Related]
32. Ad-PUMA sensitizes ovarian cancer cells to chemotherapeutic agents.
Luan QC; Sun YR; Han P; Chen Y
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4525-32. PubMed ID: 26698248
[TBL] [Abstract][Full Text] [Related]
33. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
34. Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.
Zheng X; He K; Zhang L; Yu J
Mol Cancer Ther; 2013 May; 12(5):777-86. PubMed ID: 23427294
[TBL] [Abstract][Full Text] [Related]
35. Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells.
Park SA; Park HJ; Lee BI; Ahn YH; Kim SU; Choi KS
Brain Res Mol Brain Res; 2001 Sep; 93(1):18-26. PubMed ID: 11532334
[TBL] [Abstract][Full Text] [Related]
36. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
Yang X; Fraser M; Moll UM; Basak A; Tsang BK
Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
[TBL] [Abstract][Full Text] [Related]
37. [Inhibition of mitochondrial Smac release by Akt in chemoresistant ovarian cancer cells].
Yang XK; Wang JD; Wang SY; Zhang YX
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):259-62. PubMed ID: 18788627
[TBL] [Abstract][Full Text] [Related]
38. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
39. Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells.
Wang M; Liu ZM; Li XC; Yao YT; Yin ZX
J Chemother; 2013 Jun; 25(3):162-9. PubMed ID: 23783141
[TBL] [Abstract][Full Text] [Related]
40. Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth.
Dudgeon C; Peng R; Wang P; Sebastiani A; Yu J; Zhang L
Oncogene; 2012 Nov; 31(46):4848-58. PubMed ID: 22286758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]